Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · November 19, 2023

SGLT2 Inhibitor Use and the Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction

JACC: Heart Failure


Additional Info

Disclosure statements are available on the authors' profiles:

JACC: Heart Failure
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction
JACC Heart Fail 2023 Oct 12;[EPub Ahead of Print], V Avula, G Sharma, MN Kosiborod, M Vaduganathan, TG Neilan, T Lopez, S Dent, L Baldassarre, M Scherrer-Crosbie, A Barac, J Liu, A Deswal, S Khadke, EH Yang, B Ky, D Lenihan, A Nohria, SS Dani, S Ganatra

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading